Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman | #ASH24

Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24Подробнее

Phase 1 Study of Antio-cel an Anti-BCMA CAR-T for RRMM | Michael Bishop | #ASH24Подробнее

ASH 2024: Ciara Freeman, MD on New CAR T Therapy with High Success & Manageable Side EffectsПодробнее

BMS-986393, a novel anti-GPRC5D CAR-T cell therapy, in multiple myelomaПодробнее

Ide-cel (formerly bb2121) anti-BCMA CAR T-cell therapy in relapsed/refractory MMПодробнее

A novel CAR-T cell therapy targeting BCMA is highly effective for pts with relapsed multiple myelomaПодробнее

Anti-BCMA Bispecific Antibody for Myeloma Relapse After CAR T CellsПодробнее

Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman | #ASH24Подробнее

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023Подробнее

Dr. Mailankody on BCMA CAR T-Cell Therapy in Relapsed/Refractory Multiple MyelomaПодробнее

Panel Discusses Novel BCMA-Targeted CAR-T Therapies in the Myeloma PipelineПодробнее

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myelomaПодробнее

Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory Multiple MyelomaПодробнее

BCMA-Directed CAR-T Therapy for Patients With Relapsed/Refractory Multiple MyelomaПодробнее

PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myelomaПодробнее

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple MyelomaПодробнее

Dr Hernandez-Ilizaliturri on the Use of CAR T-Cell Therapy in R/R Multiple MyelomaПодробнее

Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & MRDПодробнее